Add office photos
Employer?
Claim Account for FREE
MD Anderson Cancer Center
5.0
based on 1 Review
About MD Anderson Cancer Center
Founded in1941 (84 yrs old)
India Employee Count--
Global Employee Count10k-50k
HeadquartersHouston
Office Locations
--
Websitemdanderson.org
Primary Industry
--
Other Industries
Are you managing MD Anderson Cancer Center's employer brand? To edit company information,
claim this page for free
Texans may be proud of their state, but they're grateful to have The University of Texas M. D. Anderson Cancer Center close to home. The center has been leading the fight against cancer for more than 65 years. Located on the Texas Medical Center campus, it is devoted exclusively to cancer patient care, research, education, and prevention. Part of the University of Texas System, the tertiary-care hospital helps some 95,000 patients annually with both inpatient and outpatient care. M.D. Anderson is a premier cancer research facility and discoveries in its labs are quickly put into practice with its patients. Additionally, the hospital is a teaching facility for medical professionals and researchers.
Mission: The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.
Managing your company's employer brand?
Claim this Company Page for FREE
MD Anderson Cancer Center Ratings
based on 1 reviews
Overall Rating
5.0/5
How AmbitionBox ratings work?
5
1
4
0
3
0
2
0
1
0
Category Ratings
5.0
Company culture
5.0
Job security
5.0
Salary
5.0
Work-life balance
5.0
Skill development
5.0
Promotions
5.0
Work satisfaction
MD Anderson Cancer Center is rated 5.0 out of 5 stars on AmbitionBox, based on 1 company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Compare MD Anderson Cancer Center with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 5.0/5 based on 1 reviews | 3.7/5 based on 54.6k reviews | 4.0/5 based on 5.9k reviews | 3.9/5 based on 4.2k reviews |
Highly Rated for | Skill development Work-life balance Salary | Job security | Salary Skill development Job security | Job security Work-life balance Company culture |
Critically Rated for | No critically rated category | Promotions Salary | No critically rated category | Promotions |
Primary Work Policy | - | Hybrid 61% employees reported | Work from office 81% employees reported | Hybrid 71% employees reported |
Rating by Women Employees | - no rating available | 3.8 Good rated by 15.7k women | 4.0 Good rated by 455 women | 3.9 Good rated by 1.7k women |
Rating by Men Employees | - no rating available | 3.7 Good rated by 36.4k men | 4.0 Good rated by 5.1k men | 3.8 Good rated by 2.3k men |
Job security | 5.0 Excellent | 3.8 Good | 3.8 Good | 3.9 Good |
View more
MD Anderson Cancer Center Salaries
MD Anderson Cancer Center salaries have received with an average score of 5.0 out of 5 by 1 employees.
Manager - Marketing & Communications
(1 salaries)
Unlock
₹0.7 L/yr - ₹0.9 L/yr
Post Doctoral Fellow
(1 salaries)
Unlock
₹5.4 L/yr - ₹6.9 L/yr
Business Analyst
(1 salaries)
Unlock
₹18 L/yr - ₹23 L/yr
Histology Technician
(1 salaries)
Unlock
₹0.6 L/yr - ₹0.7 L/yr
MD Anderson Cancer Center News
March 27, 2025: Spotlight on Breakthroughs from MD Anderson Research
- The University of Texas MD Anderson Cancer Center is celebrated for its pioneering research in cancer therapy and understanding the tumor microenvironment.
- Groundbreaking studies have uncovered insights into cancer-associated fibroblasts (CAFs), revealing their spatial organization and diverse roles in tumor dynamics and therapy effectiveness.
- MD Anderson's research identified four distinct CAF subtypes across various cancers, shedding light on tumor immune phenotypes and clinical outcomes.
- Researchers at MD Anderson, including Dr. Linghua Wang and Dr. Yunhe Liu, emphasized the importance of deciphering cells' spatial organization within the tumor ecosystem for novel biomarker and therapy target identification.
- A study on combination therapies in cervical cancer patients post-surgery suggested that adding chemotherapy to radiation therapy may not significantly improve outcomes, urging a re-evaluation of treatment protocols.
- Insights into treatment resistance in SMARCA4-mutant lung cancers highlighted the impact of chromatin alterations on immune checkpoint inhibitor efficacy, proposing immune pathway modulation as a therapeutic approach.
- MD Anderson's commitment to innovative therapies is exemplified by promising results in multiple myeloma patients, particularly those with central nervous system involvement, using BCMA-directed CAR T cell therapy.
- The adoption of whole-slide imaging for remote pathological evaluations in breast cancer surgeries underscores MD Anderson's embrace of technological advancements to enhance diagnostic accuracy and surgical decision-making.
- MD Anderson's multifaceted research initiatives aim to refine cancer biology understanding and improve treatment strategies, prioritizing patient-centered outcomes and advancing the field of oncology.
- By translating complex research findings into tangible benefits for cancer patients, MD Anderson is at the forefront of driving meaningful changes in cancer treatment and survival rates.
- Through relentless research efforts and transformative therapies, MD Anderson embodies hope and progress in the fight against cancer, illuminating new pathways for healing and improved patient outcomes.
Bioengineer | 28 Mar, 2025
Rice Statistician Awarded $1 Million CPRIT Grant to Propel AI-Driven Precision Medicine for Prostate Cancer
- Rice University's statistics research professor Erzsébet Merényi and colleagues at The University of Texas MD Anderson Cancer Center have been awarded a $1 million grant from CPRIT for AI-driven precision medicine in prostate cancer research.
- The research aims to use artificial intelligence to identify lethal forms of prostate cancer earlier and improve treatment selection, potentially transforming current clinical practices and enhancing survival rates.
- Prostate cancer presents challenges due to diverse patient outcomes and resistance to traditional therapies, emphasizing the need for novel tools to understand its complexities.
- The research focuses on utilizing advanced imaging techniques to visualize metabolic shifts as potential biomarkers, with AI integration being a key aspect of overcoming analysis challenges.
- The project consists of noninvasive imaging methods for detailed tumor metabolic profiles, AI models for navigating high-dimensional datasets, and analysis of clinical data for biomarker identification.
- The research's goal is to understand metabolic signatures of lethal prostate cancer, enabling personalized interventions based on individual disease profiles for improved patient outcomes.
- By leveraging AI methodologies across scientific disciplines, this project has the potential to revolutionize prostate cancer management and may influence other areas of oncology and personalized medicine.
- The collaborative efforts between Rice University and MD Anderson Cancer Center exemplify the importance of multidisciplinary partnerships in advancing cancer treatment, showcasing the transformative impact of AI in clinical decision-making.
- This CPRIT-funded research not only signifies progress in prostate cancer management but also underscores the significant role of technological innovation and research collaboration in reshaping the future of cancer diagnosis and treatment.
- The project's emphasis on integrating advanced technology into cancer care reaffirms a commitment to scientific excellence, offering hope for novel advancements in patient care and outcomes.
Bioengineer | 19 Mar, 2025
MD Anderson Unveils Key Research Breakthroughs: Highlights from March 12, 2025
- MD Anderson Cancer Center has unveiled key research breakthroughs in cancer research, offering insights into cancer progression, treatment resistance, and outcomes across different cancer types.
- A study on pancreatic cancer revealed that epithelial-to-mesenchymal transition (EMT) plays a crucial role in tumor evolution by enhancing chromatin accessibility and genomic instability, leading to tumor heterogeneity.
- Research in advanced kidney cancer highlighted the potential of combining surgery with immunotherapy to improve patient outcomes, showing a median overall survival of 54.7 months for patients undergoing the combined approach.
- In breast cancer, the identification of the epigenetic biomarker Brd7 has implications for predicting metastatic relapse and understanding cancer dormancy at secondary sites.
- A bioinformatics chatbot, DrBioRight 2.0, has been developed to analyze proteomic data efficiently, enhancing researchers' capabilities in studying cancer proteomics and genomic changes.
- A Phase II trial on acute myeloid leukemia (AML) demonstrated the efficacy of a combination therapy (FLAG-IDA with venetoclax), achieving a remarkable overall response rate of 97% among newly diagnosed AML patients.
- In HPV-positive anal cancer, biomarker exploration identified promising markers linked to improved survival in patients undergoing immunotherapy, shedding light on potential therapeutic avenues.
- MD Anderson's integration of genomics and epigenetics is crucial for personalized medicine approaches in cancer treatment, paving the way for tailored therapies that target individual tumor profiles.
- The institution's commitment to transformative cancer research emphasizes the synergy between laboratory techniques and clinical trials, promising improved treatment strategies and patient outcomes.
- Research efforts at MD Anderson highlight the power of interdisciplinary collaboration in advancing cancer treatment, offering hope for more precise and effective therapies in the future.
- The ongoing journey of medical research underscores the importance of continuous learning and collaboration in refining treatment paradigms, uniting the scientific community and patient care arena against cancer.
Bioengineer | 12 Mar, 2025
MD Anderson Unveils Groundbreaking Research Breakthroughs – February 26, 2025
- MD Anderson Cancer Center has unveiled groundbreaking research breakthroughs in cancer research and treatment, showcasing its significant contributions to advancing oncology through collaboration among scientists and clinicians.
- Research at MD Anderson has led to the discovery of predictive biomarkers for improving treatment response forecasting in metastatic breast cancer, emphasizing the importance of immune armoring and suggesting the potential of combining CDK4/6 inhibitors with immune checkpoint inhibitors for enhanced efficacy.
- In pancreatic cancer research, the role of the TREM2 protein in tumor microenvironment regulation has been highlighted, suggesting a potential therapeutic strategy through dual-target inhibition of the IL-1β pathway.
- Insights into chromosomal changes in secondary acute myeloid leukemia (AML) have been found to be crucial in predicting survival outcomes with venetoclax-based therapies, emphasizing the significance of personalized treatment based on genetic profiles.
- Noncoding DNA mutations, particularly in ultraconserved elements (UCEs), have been linked to diverse roles in enhancing tumor suppressors or silencing oncogenes, offering new perspectives on gene regulation and therapeutic strategies in cancer.
- Studies on circulating HPV cell-free DNA in cervical cancer have highlighted its potential as a biomarker for relapse, emphasizing the importance of tailored treatment plans based on biological markers for improved patient outcomes.
- Research on metastatic non-clear cell renal cell carcinoma has shown promising results with dual immunotherapy using nivolumab and ipilimumab, underscoring the benefits of combination therapies and personalized interventions based on cancer subtype.
- MD Anderson's commitment to transforming cancer treatment through research-driven methodologies is evident in the efforts to elucidate treatment resistance mechanisms, identify biomarkers, and explore multifaceted therapeutic strategies, shaping the future of cancer care.
- These research findings confirm MD Anderson's leadership in cancer research and set the stage for further investigations into the complexities of different cancers, emphasizing precision medicine and tailored treatment approaches for improved patient care.
- As cancer research continues to advance, the integration of novel insights into patient care paradigms becomes essential for enhancing treatment outcomes, with each study contributing to a deeper understanding of cancer biology and therapeutic advancements.
Bioengineer | 27 Feb, 2025
Powered by
Compare MD Anderson Cancer Center with
Aurobindo Pharma
4.0
Hindustan Unilever
4.2
Hetero
3.9
Abbott
4.1
Alkem Laboratories
3.9
Fortis Healthcare
4.0
Parexel International
3.8
GlaxoSmithKline Pharmaceuticals
4.1
Teva Pharmaceuticals
3.9
Becton Dickinson
4.0
Kendriya Vidyalaya Sangathan
4.3
Air Liquide
3.7
Metro Group of Hospitals
3.8
Bausch & Lomb
3.8
Narayana Superspeciality Hospital
4.0
Amplifon
3.8
Teleflex Medical
3.8
Coloplast
3.3
Falck
3.2
CVS Health
3.9
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to MD Anderson Cancer Center
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
Hindustan Unilever
Biotech & Life sciences, FMCG, Healthcare / Pharma, Retail, Pharma
4.2
• 6.3k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.9
• 3.4k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.1k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.9k reviews
Fortis Healthcare
Healthcare / Pharma, Healthcare
4.0
• 2.1k reviews
Parexel International
Healthcare / Pharma, Manufacturing, Analytics & KPO, Clinical Research, Pharma
3.8
• 975 reviews
GlaxoSmithKline Pharmaceuticals
Biotech & Life sciences, Healthcare / Pharma, Manufacturing, Pharma
4.1
• 1.9k reviews
Teva Pharmaceuticals
Healthcare / Pharma, Clinical Research, Pharma
3.9
• 1.2k reviews
MD Anderson Cancer Center FAQs
When was MD Anderson Cancer Center founded?
MD Anderson Cancer Center was founded in 1941. The company has been operating for 84 years.
Where is the MD Anderson Cancer Center headquarters located?
MD Anderson Cancer Center is headquartered in Houston.
What are the pros of working in MD Anderson Cancer Center?
Working at MD Anderson Cancer Center offers several advantages that make it an appealing place for employees. The company is highly rated for company culture, job security and promotions / appraisal, based on reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
